At this International Critical Care meeting the Jet-iStar platforms (JS 800 and JS800 Plus) and the full range of Point-of-Care assays were presented with a special focus on Heparin Binding Protein (HBP), a novel patented biomarker which has been shown to play a key role in the management of Sepsis patients. Detailed presentations on the Joinstar product portfolio were made to delegates from over 20 countries and the interest from Clinicians in learning more about HBP was very encouraging and showed that there is a clear need for early biomarker(s) in Sepsis, a life-threatening disease. Of special interest to the delegates was the simplicity and ease of use of the Joinstar Jet-iStar platforms and the wide testing assay menu.